Response—letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns-Reference-Cited by-同舟云学术

Response—letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns

Published:2021-03-16 Issue:4 Volume:7 Page:e72-e73
ISSN:2055-6837
Container-title:European Heart Journal - Cardiovascular Pharmacotherapy
language:en
Short-container-title:

Author:

Galli Mattia¹²,Princi Giuseppe¹,Crea Filippo¹,D’Amario Domenico¹

Affiliation:

1. Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Largo Francesco Vito 1, Roma 00168, Italy

2. Division of Cardiology, University of Florida College of Medicine, Jacksonville, FL, USA

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvab024/37853729/pvab024.pdf

Reference11 articles.

1. Letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns;Fiolet;Eur Heart J Cardiovasc Pharmacother,2021

2. Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith;Galli;Eur Heart J Cardiovasc Pharmacother,2020

3. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy;Galli;Eur Heart J Cardiovasc Pharmacother,2020

4. Stent thrombosis with dual antithrombotic therapy in atrial fibrillation-ACS/PCI trials;Galli;J Am Coll Cardiol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Colchicine in Atherosclerosis: From Bench to Bedside;Pharmaceutics;2022-07-01

2. Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?;Therapeutic Advances in Cardiovascular Disease;2021-01